
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
Johnson & Johnson is set to buy out Crucell for around $2.3 billion (1.75 bn euros) expanding its presence in …
Dutch biopharma firm Crucell has started a phase I trial of its AdVac-based malaria vaccine in Burkina Faso, West Africa. …
GlaxoSmithKline Biologicals and Dutch vaccines company Crucell are to develop a ‘second generation’ malaria vaccine candidate. Malaria causes 900,000 deaths …
Johnson & Johnson has acquired an 18% stake in Netherlands-based vaccines firm Crucell, and the two companies will work together …
Dutch vaccines firm Crucell could be snapped up by other pharmaceutical companies after Wyeth pulled out of negotiations to buy …